A new cost-effectiveness analysis, based on the Medtronic-sponsored CRYSTAL AF trial, supports implantable cardiac monitors (ICMs) as the first option for diagnosing atrial fibrillation in patients who have suffered a stroke of uncertain origin.
Researchers led by Laura Sawyer, the scientific director of London-based consulting firm Symmetron Ltd, assessed the cost-effectiveness of ICMs in US patients who had suffered a cryptogenic stroke that may...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?